


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (currently amended) Use of the compounds of the following formula (I): A method for the treatment of neurodegenerative diseases comprising administering an effective amount of a compound of formula (I):




wherein X represents OH, (C₁₋₅)alkoxy, NH₂, NH-C₁₋₅-alkyl, or N(C₁₋₅ alkyl)₂;

R₁ is a residue derived from any of the amino acids Phe, Tyr, Trp, or Pro, each of which may optionally be substituted by a (C₁₋₅) alkoxy group, a (C₁₋₅) alkyl group or a halogen atom, and Ala, Val, Leu, or Ile;

R₂ is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu **and or** Asn;

R_3 and R_4 independently represent H, OH, (C₁-C₅) alkyl, or (C₁₋₅)alkoxy, provided that R_3 and R_4 are not both OH or (C₁₋₅)alkoxy;

R_5 represents H, OH, (C_{1-5}) alkyl or (C_{1-5}) alkoxy;
and wherein R_0 represents a group of the formula



wherein Y represents $-CO-$, $-CH_2CO-$, $-CH_2CH_2CO-$, $-CH_2CH_2CH_2CO-$, $-CH=CH-CO$ or $-OCH_2CO-$, and wherein Z represents a halogen atom, a trifluormethyl group, (C_{1-4}) alkoxy group, (C_{1-4}) alkyl group; or wherein two neighboring substituents may form a (C_{1-3}) alkylendioxy group; and wherein n is 0 or an integer of from 1 to 5;
or pharmaceutically acceptable salts thereof;.

~~for the preparation of a medicament useful in the treatment of neurodegenerative diseases.~~

2. (currently amended) The ~~use~~ method according to claim 1, wherein R_1 is a residue derived from any of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted by a (C_{1-5}) alkoxy group, a (C_{1-5}) alkyl group or a halogen atom, or a residue derived from the amino acid Ile.

3. (currently amended) The ~~use~~ method according to claim 2, wherein R_1 is a residue derived from Phe which may optionally be substituted by a (C_{1-5}) alkoxy group, a (C_{1-5}) alkyl group or a halogen atom.

4. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein X is (C_{1-5}) alkoxy, NH_2 , $NH-C_{1-5}$ alkyl, or $N(C_{1-5} \text{ alkyl})_2$.

5. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein R_2 is a residue derived from the amino acid Gly or Ile.

6. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein R_0 is a cinnamoyl moiety.

7. (currently amended) The ~~use method~~ according to ~~any of the preceding claims~~ claim 1, wherein the compound of formula (I) is cinnamoyl-glycyl-L-phenylalanyl-L-prolinamide, cinnamoyl-isoleucyl-phenylalanyl-L-proline ethylamide, cinnamoyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.